These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 18783044)

  • 61. Varenicline induced mania in a 51 year old patient without history of bipolar illness.
    Hussain S; Kayne E; Guwanardane N; Petrides G
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1162-3. PubMed ID: 21396974
    [No Abstract]   [Full Text] [Related]  

  • 62. A manic episode in a 64-year-old man: an adverse effect of varenicline.
    Ahmed AI
    Gen Hosp Psychiatry; 2011; 33(2):200.e9-200.e11. PubMed ID: 21596218
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Acute generalized exanthematous pustulosis caused by varenicline.
    Duparc A; Gosset P; Caron J; Lasek A; Modiano P
    J Eur Acad Dermatol Venereol; 2009 Sep; 23(9):1111-2. PubMed ID: 19175479
    [No Abstract]   [Full Text] [Related]  

  • 64. Smoking cessation 2008.
    Wonnacott S
    IDrugs; 2008 Apr; 11(4):256-9. PubMed ID: 18379957
    [No Abstract]   [Full Text] [Related]  

  • 65. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
    Kikkawa H; Maruyama N; Fujimoto Y; Hasunuma T
    J Clin Pharmacol; 2011 Apr; 51(4):527-37. PubMed ID: 20551220
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A longer course of varenicline therapy improves smoking cessation rates.
    Lee JH; Jones PG; Bybee K; O'Keefe JH
    Prev Cardiol; 2008; 11(4):210-4. PubMed ID: 19476573
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers.
    McColl SL; Burstein AH; Reeves KR; Billing CB; Stolar M; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):607-14. PubMed ID: 18288085
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Smoking cessation and varenicline. Do not expose or re-expose patients to its serious adverse effects!
    Prescrire Int; 2014 Sep; 23(152):208. PubMed ID: 25325119
    [No Abstract]   [Full Text] [Related]  

  • 69. Rapid assessment of cardiovascular risk among users of smoking cessation drugs within the US Food and Drug Administration's Mini-Sentinel program.
    Toh S; Baker MA; Brown JS; Kornegay C; Platt R;
    JAMA Intern Med; 2013 May; 173(9):817-9. PubMed ID: 23529063
    [No Abstract]   [Full Text] [Related]  

  • 70. [Varenicline: an aid to smoking cessation therapy].
    Perez-Bogerd S; Sternon J
    Rev Med Brux; 2007; 28(6):523-6. PubMed ID: 18265811
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Varenicline-induced acute dystonic reaction: a case report.
    Uca AU; Kozak HH; Uguz F
    Gen Hosp Psychiatry; 2014; 36(3):361.e1-2. PubMed ID: 24576987
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
    Faessel HM; Gibbs MA; Clark DJ; Rohrbacher K; Stolar M; Burstein AH
    J Clin Pharmacol; 2006 Dec; 46(12):1439-48. PubMed ID: 17101743
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.
    Williams JM; Anthenelli RM; Morris CD; Treadow J; Thompson JR; Yunis C; George TP
    J Clin Psychiatry; 2012 May; 73(5):654-60. PubMed ID: 22697191
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety of varenicline in patients with cardiovascular disease.
    Haber SL; Boomershine V; Raney E
    J Pharm Pract; 2014 Feb; 27(1):65-70. PubMed ID: 24080536
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Thoughts and acts of aggression/violence toward others reported in association with varenicline.
    Moore TJ; Glenmullen J; Furberg CD
    Ann Pharmacother; 2010 Sep; 44(9):1389-94. PubMed ID: 20647416
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Australia's experience with varenicline: usage, costs and adverse reactions.
    Walsh RA
    Addiction; 2011 Feb; 106(2):451-2. PubMed ID: 21208325
    [No Abstract]   [Full Text] [Related]  

  • 77. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.
    Faessel HM; Smith BJ; Gibbs MA; Gobey JS; Clark DJ; Burstein AH
    J Clin Pharmacol; 2006 Sep; 46(9):991-8. PubMed ID: 16920893
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Increasing the dose of varenicline in patients who do not respond to the standard dose.
    Jiménez-Ruiz CA; Barrios M; Peña S; Cicero A; Mayayo M; Cristóbal M; Perera L
    Mayo Clin Proc; 2013 Dec; 88(12):1443-5. PubMed ID: 24290118
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Varenicline: depression and suicide. Nicotine is a safer option.
    Prescrire Int; 2008 Jun; 17(95):113. PubMed ID: 18629971
    [No Abstract]   [Full Text] [Related]  

  • 80. Varenicline for smoking cessation in patients with coronary heart disease.
    Ockene I; Salmoirago-Blotcher E
    Circulation; 2010 Jan; 121(2):188-90. PubMed ID: 20048200
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.